And I'm wondering how thinking about these various therapies influences your decision making in terms of which therapy you may or may not choose for a specific patient that you're seeing in the clinic.

Yeah, that's a great question.

And I think a lot of it will be, for instance, does a patient want a subcutaneous injection or do they want pills? And every patient's a little bit different that way.

And so I think that will be a driver.

And I think as soon as we get more data and comparative data about potential risks and infections and other risks, I think that that will also be something that will go into the discussion that we have with patients.

I think it's just way too early to be able to say anything much about that.

And then the other thing would be, I mean, a lot of times patients may be told, well, you should stop this.

What do you think the ideal care team looks like as we care for these patients with CLE?

.

I'm Dr. Victoria Worth.

I'm a professor of dermatology and rheumatology at the University of Pennsylvania.

And I'm also head of dermatology at the Philadelphia VA Medical Center.

And I'm here today to mention a number of new potential therapies for cutaneous lupus.

To start with, there's lidofilamab, which is basically an antibody against BDC-A2, which is actually on plasmacytoid dendritic cells.

I'm Dr. Victoria Wirth.

I'm a professor of dermatology and rheumatology at the University of Pennsylvania in the USA.

And I'm here today to share some really interesting findings that have been presented at the UR2026 meeting in London.

England, and so we would like to talk a little bit about the role of Toll-7-8 in lupus, and we know that there's signaling that goes on through Toll-7-8 and leads to production of type 1 interferons that appear to be quite a driver for skin disease as well as systemic disease in systemic lupus and in the skin in lupus.

And therefore, there's now been an inhibitor that's been developed in Pateron that can block this signaling through this receptor, TOL7-8, which is, again, on many different cell types that seem to be important.

and when you block it you get decreased interferon in the skin.